Cartilage Oligomeric Matrix Protein Associates Differentially with Erosions and Synovitis and Has a Different Temporal Course in Cyclic Citrullinated Peptide Antibody (Anti-CCP)-positive versus Anti-CCP-negative Early Rheumatoid Arthritis

ANNE F. CHRISTENSEN, HANNE LINDEGAARD, KIM HØRSLEV-PETERSEN, MERETE L. HETLAND, BO EJBJERG, KRISTIAN STENGAARD-PEDERSEN, SØREN JACOBSEN, TINE LOTTENBURGER, TORKELL ELLINGSEN, LIS S. ANDERSEN, IB HANSEN, HENRIK SKJØDT, JENS K. PEDERSEN, ULRIK B. LAURIDSEN, ANDERS SVENDESEN, ULRIK TARP, JAN PØDENPHANT, MIKKEL ØSTERGAARD, and PETER JUNKER

ABSTRACT. Objective. Cyclic citrullinated peptide antibody (anti-CCP)-positive and anti-CCP-negative rheumatoid arthritis (RA) have been suggested as 2 distinctive disease subsets with respect to disease activity and prognosis. Previously, we proposed that anti-CCP antibodies might have a chondrocyte-suppressive effect. We aimed to compare circulating cartilage oligomeric matrix protein (COMP), a marker of cartilage turnover, in untreated anti-CCP-positive and anti-CCP-negative RA, and to study the temporal pattern of COMP through 4 years of treatment, including the relationship to imaging and clinical findings.

Methods. A total of 160 patients with newly diagnosed RA who were naive to disease-modifying antirheumatic drugs were included in the CIMESTRA trial. Ninety healthy blood donors served as controls. Demographic and disease measures including Disease Activity Score in 28 joints, IgM rheumatoid factor, anti-CCP, Health Assessment Questionnaire, visual analog scale scores for pain and global and physician assessment, and magnetic resonance imaging (MRI) of the nondominant hand were recorded at baseline. COMP in serum was measured by ELISA at inclusion and serially through 4 years.

Results. Median baseline COMP was higher in patients with RA [9.8 U/l (interquartile range 8.96, 10.5)] compared with controls [8.3 U/l (IQR 7.84, 8.9); p < 0.001] and remained elevated at 4 years [10.8 U/l (IQR 10.2, 11.7); p < 0.001]. At baseline, anti-CCP-positive patients had lower COMP than anti-CCP-negative patients (p = 0.048). In anti-CCP-positive patients, COMP exhibited a parabolic course over 4 years, while COMP in anti-CCP-negative patients had an almost linear course. In anti-CCP-positive patients, COMP was associated with MRI edema and erosion score, while COMP was correlated with synovitis score in anti-CCP-negative individuals.

Conclusion. Our study provides additional evidence for the existence of different disease pathways in anti-CCP-positive and anti-CCP-negative subsets of RA, and evidence that anti-CCP antibodies may be implicated in the disease process by modifying cartilage metabolism. (First Release May 15 2011; J Rheumatol 2011;38:1563–8; doi:10.3899/jrheum.101241)

Key Indexing Terms: RHEUMATOID ARTHRITIS, CARTILAGE, CYCLIC CITRULLINATED PEPTIDE ANTIBODY, AUTOANTIBODIES, SYNOVITIS, CARTILAGE OLIGOMERIC MATRIX PROTEIN
Cartilage oligomeric matrix protein (COMP), a member of the thrombospondin glycoprotein family, is an extracellular matrix protein mainly expressed in cartilaginous tissue. Excess release of COMP leading to elevated levels in serum has been reported in various joint diseases, osteoarthritis and rheumatoid arthritis (RA) in particular. While some studies have suggested that increased COMP in the circulation is a predictor of joint destruction of large and small joints in RA, discrepant results have been reported by others. These disparities may be attributable to differences in the study populations, e.g., with respect to cyclic citrullinated peptide antibody (anti-CCP) seropositivity. Thus, Turesson, et al recently reported increased COMP levels in individuals who developed RA within 1–2 years, and elevated COMP was more likely in anti-CCP-negative subjects than in anti-CCP-positive individuals. We recently reported that the N-propeptide of collagen IIA (PIANP), a marker of cartilage collagen anabolism, is significantly lower in anti-CCP-positive compared to anti-CCP-negative patients with RA. As well, we found a negative correlation between PIANP and anti-CCP titer in serum. These observations indicate that autoimmunity reflected by anti-CCP is implicated in the pathogenesis of RA by suppressing collagen II formation. Since COMP in serum is widely considered to be a reliable molecular marker of cartilage turnover, we undertook this investigation in order to compare circulating COMP in newly diagnosed, untreated anti-CCP-positive versus anti-CCP-negative RA; to elucidate the temporal COMP pattern in these 2 subsets; and to study the relationship between COMP and baseline magnetic resonance imaging (MRI) findings and disease activity measures.

MATERIALS AND METHODS

Patients and controls. A total of 160 patients with newly diagnosed untreated RA were included in the CIMESTRA trial. Briefly, patients fulfilled the American College of Rheumatology (ACR) 1987 revised criteria for RA. Further inclusion criteria were disease duration < 6 months, ≥ 2 swollen joints at baseline, and age 18–75 years. Health Assessment Questionnaire (HAQ) score, 0–3) is an analog scale (VAS; 1–10) for pain and global and physician assessment, and Disease Activity Score in 28 joints (DAS28) was calculated and ACR response was recorded. Ninety healthy blood donors (45 women, 45 men; median age 42.5 yrs, range 23–64 yrs) served as controls. In this healthy cohort, no other biochemical or clinical data were available and COMP was measured only once.

The RA treatment strategy aimed at achieving maximal synovitis control methotrexate (MTX) plus cyclosporine compared to MTX and placebo. In addition, patients in both groups received intraarticular betamethasone injections into swollen joints (7 mg/l, maximum 4 joints or 4 ml per visit). After one year, hydroxychloroquine was added and cyclosporine/placebo was tapered to zero, while MTX and synovitis suppression by intraarticular steroid injections into swollen joints were continued. During an open extension through study years 3–4 the strategy of maximal synovitis suppression was pursued. Oral glucocorticoids were allowed during the open extension study.

The trial was approved by the local ethics committee (j. no. M1995-98) and fulfilled the Declaration of Helsinki and the International Conference on Harmonisation 1996 revised guidelines for Good Clinical Practice (j. no. NCT00209859). Signed informed consent was obtained from all study participants. The RA treatment strategy aimed at achieving maximal synovitis control methotrexate (MTX) plus cyclosporine compared to MTX and placebo. In addition, patients in both groups received intraarticular betamethasone injections into swollen joints (7 mg/l, maximum 4 joints or 4 ml per visit). After one year, hydroxychloroquine was added and cyclosporine/placebo was tapered to zero, while MTX and synovitis suppression by intraarticular steroid injections into swollen joints were continued. During an open extension through study years 3–4 the strategy of maximal synovitis suppression was pursued. Oral glucocorticoids were allowed during the open extension study.

The trial was approved by the local ethics committee (j. no. M1995-98) and fulfilled the Declaration of Helsinki and the International Conference on Harmonisation 1996 revised guidelines for Good Clinical Practice (j. no. NCT00209859). Signed informed consent was obtained from all study participants.
described\textsuperscript{13,26}. The 2 treatment arms did not differ in baseline characteristics except for a higher proportion of anti-CCP-positive patients in the MTX/cyclosporine versus the MTX/placebo group (57/80 vs 36/80; \( p < 0.001 \)). The need for glucocorticoids was higher during the first 2 years compared with the open extension study\textsuperscript{18}. During the open extension study the cumulative dose of glucocorticoids corresponded to 0.09 (IQR 0–0.38) mg prednisolone per day (intraarticular and oral) compared to 0.97 (0.5–1.7) mg per day the first 2 years\textsuperscript{18}. There was no difference in the cumulative doses of intraarticular betamethasone administered during the first 2 years between the 2 treatment arms [MTX/placebo vs MTX/cyclosporine: 14.4 ml (7.5–19.8) vs 11 ml (7–17.1); \( p = 0.10 \)]. The cumulative dose was significantly higher during the first year compared with the subsequent years\textsuperscript{26}. Similarly, no difference was observed between anti-CCP-positive and anti-CCP-negative patients with respect to the total intraarticular glucocorticoid dose [12 ml (8.1–21.3) vs 12 ml (7–19); \( p = 0.37 \)]. Including the cumulative dose of steroids used in the open extension study, again no difference was observed between the treatment arms or anti-CCP status (data not shown). In the RA population there was a statistically significant female preponderance (107/160 vs 45/90; \( p = 0.01 \)), and the RA patients were older than the controls [52.9 (41.8–62.5) yrs vs 42.5 (31–53) yrs; \( p < 0.001 \)].

One hundred thirty-four patients had data available for composite disease activity measures at 4-year followup, and 103/134 (77%), 86/134 (64%), and 89/134 (66%) achieved ACR50, ACR70, and DAS28 < 2.6, respectively.

**COMP in serum.** COMP exhibited an age-dependent increase in RA patients and healthy controls (rho = 0.29, \( p = 0.0002 \), and rho = 0.27, \( p = 0.01 \), respectively). Further, the level of COMP was significantly higher among male compared to female patients with RA [11.5 U/l (IQR 9.4–13.5) vs 8.9 U/l (7.8–11); \( p < 0.001 \)]. There was no significant difference in COMP levels between the sexes in controls [8.5 U/l (7.6–10.4) vs 8.0 U/l (7.3–9.4); \( p = 0.13 \)].

At baseline, circulating COMP was increased in RA patients compared to controls [9.8 U/l (IQR 8.1–12.1) vs 8.3 U/l (7.4–9.8); \( p = 0.001 \)], even adjusted for age and sex (\( p = 0.001 \)). COMP remained elevated at 4 years [10.8 (8.5–13.7); \( p < 0.001 \)]. Stratification according to anti-CCP status showed that this increase applied to both subsets, but that COMP was significantly lower in anti-CCP-positive versus anti-CCP-negative patients [9.0 U/l (IQR 7.8–11.8) vs 10.5 U/l (8.4–13.1); \( p = 0.048 \); Figure 1]. The same trend was observed after 4 years [10.2 U/l (8.3–13.4) vs 11.7 U/l (9.6–14.3); \( p = 0.055 \)].

At baseline, COMP was also lower among IgM-RF-positive compared to IgM-RF-negative patients [9.1 U/l (IQR 7.8–11.8) vs 10.1 U/l (8.6–13.3); \( p = 0.047 \)].

An inverse correlation was observed between COMP and anti-CCP titer at baseline (rho = -0.17, \( p = 0.03 \)). No difference in COMP was observed regarding shared epitope status (\( p = 0.26 \)) or smoking status (\( p = 0.61 \)).

There was no difference in baseline COMP values between patients who achieved DAS28 < 2.6 (\( p = 0.48 \)) or ACR70 response (\( p = 0.21 \)) compared with patients who did not achieve DAS28 < 2.6 or ACR70 response after 4 years.

There was no difference between anti-CCP-positive and anti-CCP-negative patients with respect to demographic or clinical variables, except that anti-CCP-positive patients had fewer tender joints [8 (5–15) vs 11 (7–16); \( p = 0.02 \)] and were more frequently carriers of the SE [82/93 (88%) vs 34/65 (52%); \( p < 0.001 \)] compared with anti-CCP-negative individuals.

The associations between baseline COMP and clinical variables at baseline are outlined in Table 1.

The temporal course of COMP in RA serum exhibited a parabolic configuration (Figure 2A; \( \beta_{\text{time}}^2 = -8.37 \times 10^{-6}, p = 0.004 \)) irrespective of age and sex (data not shown). This parabolic course was confined to the anti-CCP-seropositive subset (\( \beta_{\text{time}}^2 = -1.3 \times 10^{-5}, p = 0.001 \)), while an almost linear course was observed in anti-CCP-negative subjects (\( \beta_{\text{time}}^2 = -1.3 \times 10^{-6}, p = 0.77 \); Figure 2B).

From baseline and 12 months onward, COMP increased in anti-CCP-positive patients [9 U/l (IQR 7.8–11.8) vs 11.3 U/l (8.6–14); \( p < 0.001 \)], while there was no significant difference in anti-CCP-negative subjects during this period [10.5 U/l (8.4–13.1) vs 11.3 U/l (8.7–13.7); \( p = 0.55 \)]. Although not statistically significant, COMP tended to decrease from years 1 through 4 in anti-CCP-positive patients [11.3 U/l (8.6–14) vs
The Journal of Rheumatology 2011; 38:8; doi:10.3899/jrheum.101241

The wrist-only MRI group (n = 135) and the wrist+MCP MRI group (n = 93) did not differ in baseline variables including anti-CCP status\textsuperscript{19}. Baseline COMP correlated significantly, although weakly, with MRI wrist-only erosion and synovitis scores (rho = 0.25, p = 0.0043, and rho = 0.25, p = 0.0039, respectively). Stratifying the cohort according to anti-CCP status, COMP correlated similarly to the erosion score in anti-CCP-positive individuals (n = 81) but not in anti-CCP-negative individuals (n = 53; Table 1). By contrast, COMP was weakly associated with synovitis score in anti-CCP-negative individuals (Table 1). In the wrist+MCP MRI group the same trend was observed for the erosion score [anti-CCP-positive (n = 53): rho = 0.28, p = 0.04; and anti-CCP-negative (n = 36): rho = 0.14, p = 0.40], but not for the synovitis score (data not shown). The MRI edema score was associated with COMP in the anti-CCP-positive patients in the wrist-only and wrist+MCP MRI groups (rho = 0.26, p = 0.017, and rho = 0.32, p = 0.016, respectively).

### DISCUSSION

In this study, we add to previous evidence that COMP in the circulation is increased in patients with newly diagnosed RA. Of note, however, this increment was less pronounced in anti-CCP-positive compared to anti-CCP-negative individuals, and in addition, there was an inverse correlation between COMP in serum and anti-CCP titer. Further, we found that in anti-CCP-negative individuals, circulating COMP followed a parabolic 4-year course, whereas there was an almost linear pattern in anti-CCP-negative patients. In anti-CCP-positive patients, COMP was associated with MRI erosion and edema score, while COMP correlated positively with MRI synovitis scores in anti-CCP-negative subjects.

Our finding of lower COMP in anti-CCP-positive compared with anti-CCP-negative patients is in accord with a recent report by Turesson, et al\textsuperscript{11}. These authors reported that individuals who developed RA had higher prediagnostic COMP levels 1–2 years before RA diagnosis compared with matched controls, but that this increment was particularly prevalent in anti-CCP-negative preclinical RA\textsuperscript{11}.

In a study on the N-propeptide of collagen IIA (PIIANP), a marker of collagen II anabolism, we found that circulating PIIANP was significantly lower in anti-CCP-positive compared to anti-CCP-negative patients with RA\textsuperscript{12}. In addition, there was a negative correlation between PIIANP and anti-CCP titer. These observations support the thesis that antibodies against citrullinated peptides may have a cartilage-suppressive effect. This is supported by chondrocyte culture studies and animal experiments, where antibodies against citrullinated peptides, e.g., collagen II and fibrinogen, have been reported to induce arthritis and to aggravate preexisting experimental arthritis\textsuperscript{27,28,29}. Considering that bone marrow edema has been shown to be a strong predictor of future erosive progression\textsuperscript{18,19}, the potential pathogenicity of anti-CCP is further supported in this study, where we report a positive correlation between COMP and MRI edema and erosion scores in patients who are anti-CCP-positive. Further evidence for differential pathogenic pathways in anti-CCP-positive and anti-CCP-negative RA patients appears from the correlation between COMP and MRI synovitis scores and not erosion scores in anti-CCP-negative subjects observed in our study.

The CIMESTRA treatment protocol on which this study is based has been reported to be particularly efficient with respect to suppression of signs and symptoms of RA and erosive progression\textsuperscript{13,18,26}. Since COMP is considered to be an integral component in cartilage growth and regeneration\textsuperscript{30,31}, it would be anticipated that suppression of joint inflammation would lead to increased formation and release of COMP into the circulation. This is supported by the COMP increment fol-

Table 1. Associations between cartilage oligomeric matrix protein (COMP) and clinical variables at baseline in patients with early untreated rheumatoid arthritis. Spearman rank correlation rho values.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>COMP at Baseline, n = 160</th>
<th>COMP at Baseline, Anti-CCP-positive, n = 93</th>
<th>COMP at Baseline, Anti-CCP-negative, n = 66</th>
</tr>
</thead>
<tbody>
<tr>
<td>C-reactive protein</td>
<td>0.10</td>
<td>0.13</td>
<td>0.14</td>
</tr>
<tr>
<td>DAS28</td>
<td>0.28*</td>
<td>0.28*</td>
<td>0.27*</td>
</tr>
<tr>
<td>No. swollen joints</td>
<td>0.39*</td>
<td>0.32*</td>
<td>0.47*</td>
</tr>
<tr>
<td>No. tender joints</td>
<td>0.29*</td>
<td>0.27*</td>
<td>0.26*</td>
</tr>
<tr>
<td>MRI synovitis score*</td>
<td>0.25*</td>
<td>0.22*</td>
<td>0.32*</td>
</tr>
<tr>
<td>MRI erosion score*</td>
<td>0.25*</td>
<td>0.37*</td>
<td>0.13</td>
</tr>
<tr>
<td>MRI edema score*</td>
<td>0.18*</td>
<td>0.26*</td>
<td>0.14</td>
</tr>
<tr>
<td>HAQ</td>
<td>0.11</td>
<td>0.20</td>
<td>0.04</td>
</tr>
<tr>
<td>VAS global</td>
<td>0.07</td>
<td>0.10</td>
<td>0.05</td>
</tr>
<tr>
<td>VAS pain</td>
<td>0.09</td>
<td>0.17</td>
<td>–0.02</td>
</tr>
<tr>
<td>VAS physician</td>
<td>0.34*</td>
<td>0.25*</td>
<td>0.44*</td>
</tr>
</tbody>
</table>

\* p ≤ 0.05; \*\* p ≤ 0.01. † Contrast-enhanced MRI of nondominant wrist (n = 135). CCP: cyclic citrullinated peptides; DAS28: Disease Activity Score including 28 joints; VAS: visual analog scale score; HAQ: Health Assessment Questionnaire.
Following initiation of synovitis-suppressive treatment (Figure 2A). However, the parabolic course in the anti-CCP-positive subset, which exhibited a peak value followed by gradual decline through years 1–4, probably reflects that complete regeneration of cartilage metabolism cannot be achieved despite early and aggressive treatment. Thus, the lower COMP in longstanding RA among anti-CCP-positive individuals may reflect a modifier effect by these autoantibodies on cartilage metabolism. Alternatively, these different patterns may reflect that increased cartilage turnover occurs in a subset that is distinct from the RA phenotype characterized by anti-CCP, and that COMP may have different implications in these 2 disease categories. In addition, in anti-CCP-positive patients, paracrine and/or autocrine signaling from the juxtaarticular bone compartment may contribute to cartilage depletion, as shown by the baseline association between COMP and MRI edema score in anti-CCP-seropositive patients. The potential significance of anti-CCP antibodies is emphasized by the observation that COMP did not differ according to shared epitope status or smoking habit. This indicates that anti-CCP antibodies interfere with RA disease mechanisms that are not shared with these well established risk factors for RA.

The study has some limitations and issues to be considered. First, COMP was measured only once in the control cohort, implying that potential temporal changes related to, for example, age or future health status are missed. Second, approximately 40% failed to complete the study followup. However, there was no difference with respect to baseline characteristics between completers and noncompleters and the intention-to-treat analysis included a large majority of the cohort. Third, the CIMESTRA cohort was offered intraarticular betamethasone injections whenever swollen joints were present. Hence, the different temporal courses of COMP according to anti-CCP status could in theory be attributable to different steroid dosing in the 2 subsets. However, no difference was observed between the 2 subsets with respect to their cumulative steroid doses.

Our study provides further evidence for the existence of different disease pathways between anti-CCP-positive and anti-CCP-negative subsets of RA, and evidence that anti-CCP antibodies may be implicated in the disease process by modifying cartilage metabolism.

ACKNOWLEDGMENT

We appreciate the expert laboratory assistance by Kirsten Junker at Medical Biotechnology Centre, University of Southern Denmark, Odense; Prof. Peter Garred at the Department of Clinical Immunology at Rigshospitalet, Copenhagen University Hospital; and Prof. Niels Heegaard at the Department of Biochemistry and Immunology, Statens Serum Institut, Denmark.

REFERENCES


